Description

Axogen’s $270 Million Revenue Target: Can Nerve Repair Adoption Keep Scaling?

Axogen, Inc. reported financial results for the first quarter of 2026 reflecting a 26.6% year-over-year revenue increase to $61.5 million, supported by broad-based growth across its three principal markets: extremities, oral maxillofacial (OMF) and head and neck, and breast reconstruction. The company emphasized strong commercial execution, with sales force productivity exceeding expectations and an expanded active surgeon count, signaling increasing adoption of Axogen’s nerve repair algorithm and contributing to revenue growth. Adjusted EBITDA rose to $5.7 million, or 9.3% of revenue, showing improved operational leverage compared to the prior year. Axogen’s market development efforts revealed that each segment is progressing but remains underpenetrated. The extremities market, with an estimated total addressable market (TAM) of $2.9 billion, continues to mature with ongoing market education and standard-of-care development. The breast segment, powering the fastest growth, faces challenges related to patient awareness of numbness after mastectomy and the availability of treatment options.